Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17777287 | 0.85 | MGLL (0.33) | MGLLGLA | |
| SCHEMBL2570463 | 0.85 | MGLL (0.33) | MGLLGLA | |
| SCHEMBL6699078 | 0.85 | MGLL (0.33) | MGLLGLA | |
| SCHEMBL13989239 | 0.82 | MGLL (0.31) | MGLL | |
| SCHEMBL12468909 | 0.82 | MGLL (0.31) | MGLL | |
| SCHEMBL23619542 | 0.82 | MGLL (0.34) | MGLL | |
| SCHEMBL17664956 | 0.82 | MGLL (0.31) | MGLL | |
| SCHEMBL260599 | 0.82 | MGLL (0.34) | MGLLGLA | |
| SCHEMBL13447721 | 0.80 | MGLL (0.33) | MGLLGLA | |
| SCHEMBL10074884 | 0.80 | MGLL (0.31) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2010033207-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20090221471-A1 | PRODRUGS OF VANCOMYCIN WITH HYDROLYSIS RESISTANT POLYMER LINKAGES | ENZON PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | MGLL 4175/4885GLA 2752/4885 |
| US-20090221471-A1 | PRODRUGS OF VANCOMYCIN WITH HYDROLYSIS RESISTANT POLYMER LINKAGES | SI, DNPEP, PEPD | MGLL 1430/4885GLA 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.